NEW YORK, July 31 (Reuters) - Drugmaker Schering-Plough Corp. on Monday said Japanese regulators approved its Temodal treatment for a type of brain tumor known as malignant glioma.
The approval follows a priority review of the new drug application in Japan, which was granted in September 2005 in order to satisfy an unmet medical need in Japanese patients.
Temodal, marketed as Temodar in the U.S., is approved in 77 countries.